|
AU2016203996A1
|
|
Indazole, benzisoxazole and benzisothiazole kinase inhibitors
|
|
AU2015255201A1
|
|
Monohydrate of an azaadamantane derivative
|
|
AU2015213384A1
|
|
Process for preparing antiviral compound
|
|
AU2014280939A1
|
|
Uracil or thymine derivative for treating hepatitis C
|
|
AU2014203655A1
|
|
Anti-viral compounds
|
|
AU2013263839A1
|
|
Indazole, benzisoxazole and benzisothiazole kinase inhibitors
|
|
AU2013216616A1
|
|
Cyclopropyl amine derivatives
|
|
AU2012203831A1
|
|
Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands
|
|
NZ715562A
|
|
Anti-viral compounds
|
|
UA110802C2
|
|
Monohydrate of derivative of azaadamantane
|
|
TW201202235A
|
|
Crystalline forms of kinase inhibitors
|
|
TW201204736A
|
|
Crystalline forms of kinase inhibitors
|
|
NZ605440A
|
|
Solid compositions comprising an hcv inhibitor
|
|
EA021570B1
|
|
Solid compositions for the treatment of hcv infections (embodiments)
|
|
ZA201008890B
|
|
A process for the preparation of the apoptosis promoter abt-263
|
|
PE20141083A1
|
|
ANTIVIRAL COMPOUNDS
|
|
TW200942519A
|
|
Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
|
|
CN104230893A
|
|
2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
|
|
EP2639226A1
|
|
Anti-infective pyrimidines and uses thereof
|
|
TW200821299A
|
|
Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
|
